Are you a new member? Sign up now
Login area
| Sign up
close
OGIVRI - 440mg - 1
| ATC | B/G | Ingredients | code | Registration Nb | brand_name | Dosage | Presentation | Form | Route | Agent | Laboratory | man_country | Price | Pharmacist Margin | Startum | Responsible Party Name | Responsible Party Country | Exch_date | %SUBSIDY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| L01FD01 | BioTech | Trastuzumab - 440mg | 11519 | 114723/1 | OGIVRI | 440mg | 1 | Injectable lyophilised powder | Infusion | Droguerie de l'Union | Biocon Biologics Limited | India | 80,027,615 L.L | 2.44 | E2 | Biosimilars Newco Limited | UK | 2/5/2024 | 0 |
Drug Substitutes
| ATC | B/G | Ingredients | code | Registration Nb | brand_name | Dosage | Presentation | Form | Route | Agent | Laboratory | man_country | Price | Pharmacist Margin | Startum | Responsible Party Name | Responsible Party Country | Exch_date | %SUBSIDY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| L01FD01 | BioTech | Trastuzumab - 440mg | 10326 | 200319/1 | ARYOTRUST | 440mg | 1 | Injectable powder for concentrate for solution + solvent | Infusion | Lebiran SARL | Aryogen Pharmed | Iran | 34,948,930 L.L | 2.44 | E2 | Aryogen Pharmed | Iran | 2/5/2024 | 0 |
| L01FD01 | BioTech | Trastuzumab - 440mg | 8053 | 11015/1 | HERCEPTIN | 21mg/ml | 1 | Injectable concentrated powder for solution+diluent | Infusion | Omnipharma | Genentech Inc, Hillsboro, Oregon | USA | 166,423,476 L.L | 2.44 | E2 | F. Hoffmann La Roche Ltd | Switzerland | 2/5/2024 | 0 |
| L01FD01 | BioTech | Trastuzumab - 440mg | 9458 | 53618/1 | HERCEPTIN | 21mg/ml | 1 | Injectable concentrated powder for solution+diluent | Infusion | Omnipharma | Genentech Inc | USA | 166,423,476 L.L | 2.44 | E2 | F. Hoffmann La Roche Ltd | Switzerland | 2/5/2024 | 0 |
| L01FD01 | BioTech | Trastuzumab - 440mg | 10653 | 177019/1 | HERZUMA | 440mg | 1 | Injectable powder for concentrate for solution | Infusion | Droguerie Mercury S.A.L. | Celltrion Inc. | Korea | 89,170,219 L.L | 2.44 | E2 | Hikma Pharmaceuticals | Jordan | 2/5/2024 | 0 |
| L01FD01 | BioTech | Trastuzumab (r-DNA origin) - 440mg | 9394 | 138015/1 | MABTIN 440 | 440mg | 1+1 bacteriostatic water | Injectable powder for solution | Infusion | Benta Trading Co s.a.l. | Biocon Biologics Limited, India, for Benta SAL | Lebanon | 70,042,700 L.L | 10.71 | E1 | 2/5/2024 | 0 | ||
| L01FD01 | BioTech | Trastuzumab - 440mg | 11584 | 106823/1 | TRASTUREL | Levant Pulse SARL | Reliance Life Sciences pvt Ltd | India | 52,047,114 L.L | 10.71 | E1 | Reliance Life Sciences pvt Ltd | India | 2/5/2024 | 0 | ||||
| L01FD01 | BioTech | Trastuzumab - 440mg | 10212 | 38220/1 | TRAZIMERA | 440mg | 1 | Injectable powder for solution+solvent | Infusion | Droguerie Fattal S.A.L. | Pfizer Manufacturing Belgium NV | Belgium | 75,295,202 L.L | 10.71 | E1 | pfizer Canada ULC | Canada | 2/5/2024 | 0 |
| L01FD01 | BioTech | Trastuzumab - 440mg | 11584/388 | 106823/1 | TRASTUREL | Levant Pulse SARL | Reliance Life Sciences pvt Ltd | India | L.L | 10.71 | E1 | Reliance Life Sciences pvt Ltd | India | 2/5/2024 |
Sitemap
© Copyrights reserved to Ministry of Public Health 2024